Kangmei Pharmaceutical Co Ltd operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Kangmei Pharmaceutical Co Ltd with three other
companies in this sector in China:
China Resources Double-Crane Pharmaceutical Company Limited
sales of 6.42 billion Chinese Renmimbi [US$929.11 million]
of which 68%
was Non- transfusion),
Zhejiang Nhu Co Ltd
(6.23 billion Chinese Renmimbi [US$900.84 million]
of which 95%
was Pharmaceutical Chemicals), and
Apeloa Pharmaceutical Co Ltd
(5.55 billion Chinese Renmimbi [US$803.23 million]
of which 100%
was Health Care & Pharmaceutical).
Kangmei Pharmaceutical Co Ltd reported sales of 26.48 billion Chinese Renmimbi (US$3.83 billion)
December of 2017.
increase of 22.5%
versus 2016, when the company's sales were 21.61 billion Chinese Renmimbi.
Sales at Kangmei Pharmaceutical Co Ltd have increased during each of the previous five years
(and since 2012, sales have increased a total of 137%).
Sales of Other Operation saw an increase
that was more than double the company's growth rate: sales were up
67.7% in 2017, from
66.58 million Chinese Renmimbi to 111.67 million Chinese Renmimbi.
Not all segments of Kangmei Pharmaceutical Co Ltd experienced an increase in sales in 2017:
sales of Other (Main) fell 17.1% to 781.85 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).